Literature DB >> 33323965

G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer.

Christopher J Bergin1, Aïcha Zouggar1, Joshua R Haebe1, Angelique N Masibag1, François M Desrochers1, Simon Y Reilley1, Gautam Agrawal1, Yannick D Benoit2.   

Abstract

Colorectal tumors are hierarchically organized and governed by populations of self-renewing cancer stem cells, representing one of the deadliest types of cancers worldwide. Emergence of cancer stemness phenotype depends on epigenetic reprogramming, associated with profound transcriptional changes. As described for pluripotent reprogramming, epigenetic modifiers play a key role in cancer stem cells by establishing embryonic stem-like transcriptional programs, thus impacting the balance between self-renewal and differentiation. We identified overexpression of histone methyltransferase G9a as a risk factor for colorectal cancer, associated with shorter relapse-free survival. Moreover, using human transformed pluripotent cells as a surrogate model for cancer stem cells, we observed that G9a activity is essential for the maintenance of embryonic-like transcriptional signature promoting self-renewal, tumorigenicity, and undifferentiated state. Such a role was also applicable to colorectal cancer, where inhibitors of G9a histone methyltransferase function induced intestinal differentiation while restricting tumor-initiating activity in patient-derived colorectal tumor samples. Finally, by integrating transcriptome profiling with G9a/H3K9me2 loci co-occupancy, we identified the canonical Wnt pathway, epithelial-to-mesenchyme transition, and extracellular matrix organization as potential targets of such a chromatin regulation mechanism in colorectal cancer stem cells. Overall, our findings provide novel insights on the role of G9a as a driver of cancer stem cell phenotype, promoting self-renewal, tumorigenicity, and undifferentiated state.

Entities:  

Year:  2020        PMID: 33323965      PMCID: PMC7878189          DOI: 10.1038/s41388-020-01591-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis.

Authors:  Nirit Feldman; Ariela Gerson; Jia Fang; En Li; Yi Zhang; Yoichi Shinkai; Howard Cedar; Yehudit Bergman
Journal:  Nat Cell Biol       Date:  2006-01-15       Impact factor: 28.824

2.  Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.

Authors:  Tathiane M Malta; Artem Sokolov; Andrew J Gentles; Tomasz Burzykowski; Laila Poisson; John N Weinstein; Bożena Kamińska; Joerg Huelsken; Larsson Omberg; Olivier Gevaert; Antonio Colaprico; Patrycja Czerwińska; Sylwia Mazurek; Lopa Mishra; Holger Heyn; Alex Krasnitz; Andrew K Godwin; Alexander J Lazar; Joshua M Stuart; Katherine A Hoadley; Peter W Laird; Houtan Noushmehr; Maciej Wiznerowicz
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

Review 3.  Cancer stem cells: current status and evolving complexities.

Authors:  Jane E Visvader; Geoffrey J Lindeman
Journal:  Cell Stem Cell       Date:  2012-06-14       Impact factor: 24.633

4.  A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer.

Authors:  Felipe de Sousa e Melo; Antonina V Kurtova; Jonathan M Harnoss; Noelyn Kljavin; Joerg D Hoeck; Jeffrey Hung; Jeffrey Eastham Anderson; Elaine E Storm; Zora Modrusan; Hartmut Koeppen; Gerrit J P Dijkgraaf; Robert Piskol; Frederic J de Sauvage
Journal:  Nature       Date:  2017-03-29       Impact factor: 49.962

5.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

Authors:  Catherine A O'Brien; Aaron Pollett; Steven Gallinger; John E Dick
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

6.  An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.

Authors:  Ittai Ben-Porath; Matthew W Thomson; Vincent J Carey; Ruping Ge; George W Bell; Aviv Regev; Robert A Weinberg
Journal:  Nat Genet       Date:  2008-05       Impact factor: 38.330

7.  Transcriptional and epigenetic dynamics during specification of human embryonic stem cells.

Authors:  Casey A Gifford; Michael J Ziller; Hongcang Gu; Cole Trapnell; Julie Donaghey; Alexander Tsankov; Alex K Shalek; David R Kelley; Alexander A Shishkin; Robbyn Issner; Xiaolan Zhang; Michael Coyne; Jennifer L Fostel; Laurie Holmes; Jim Meldrim; Mitchell Guttman; Charles Epstein; Hongkun Park; Oliver Kohlbacher; John Rinn; Andreas Gnirke; Eric S Lander; Bradley E Bernstein; Alexander Meissner
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

8.  Module map of stem cell genes guides creation of epithelial cancer stem cells.

Authors:  David J Wong; Helen Liu; Todd W Ridky; David Cassarino; Eran Segal; Howard Y Chang
Journal:  Cell Stem Cell       Date:  2008-04-10       Impact factor: 24.633

Review 9.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

Review 10.  Epigenetics of colorectal cancer: biomarker and therapeutic potential.

Authors:  Gerhard Jung; Eva Hernández-Illán; Leticia Moreira; Francesc Balaguer; Ajay Goel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-01-03       Impact factor: 46.802

View more
  6 in total

1.  Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.

Authors:  Kwang-Su Park; Yan Xiong; Hyerin Yim; Julia Velez; Nicolas Babault; Prashasti Kumar; Jing Liu; Jian Jin
Journal:  J Med Chem       Date:  2022-06-28       Impact factor: 8.039

Review 2.  Targeting Cancer Stem Cells through Epigenetic Modulation of Interferon Response.

Authors:  Jau-Ling Huang; Si-Yun Chen; Chang-Shen Lin
Journal:  J Pers Med       Date:  2022-04-01

Review 3.  Emerging role of G9a in cancer stemness and promises as a therapeutic target.

Authors:  Joshua R Haebe; Christopher J Bergin; Tamara Sandouka; Yannick D Benoit
Journal:  Oncogenesis       Date:  2021-11-13       Impact factor: 7.485

4.  Protocol for serial organoid formation assay using primary colorectal cancer tissues to evaluate cancer stem cell activity.

Authors:  Christopher J Bergin; Yannick D Benoit
Journal:  STAR Protoc       Date:  2022-03-04

5.  Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1.

Authors:  Enrique de Álava; Lourdes Hontecillas-Prieto; Daniel J García-Domínguez; Nabil Hajji; Roser López-Alemany; Sara Sánchez-Molina; Elisabet Figuerola-Bou; Francisco J Morón Civanto; Santiago Rello-Varona; Eduardo Andrés-León; Adrián Benito; Hector C Keun; Jaume Mora; Óscar M Tirado
Journal:  Oncogene       Date:  2022-03-30       Impact factor: 8.756

6.  VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer.

Authors:  Nikhil Baban Ghate; Sangnam Kim; Erin Spiller; Sungmin Kim; Yonghwan Shin; Suhn K Rhie; Goar Smbatyan; Heinz-Josef Lenz; Shannon M Mumenthaler; Woojin An
Journal:  Mol Oncol       Date:  2021-08-08       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.